Safety of Autologous-bone-marrow Injections up to 2 weeks post-procedure, 3 months and 6 months [clinicaltrials_resource:4aaeb1ce2dea250ee19040786353f6a7]
Safety of cell injections was assessed by reviewing adverse events at 3 time points: (1) up to 2 weeks post-procedure), (2) 3 months post-procedure, and (3) at 6 months post-procedure. Major adverse events were adjudicated (hospitalization, arrhythmia, exacerbation of congestive HF [CHF], acute coronary syndrome, myocardial infarction, stroke, or death).
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Safety of Autologous-bone-marrow Injections up to 2 weeks post-procedure, 3 months and 6 months [clinicaltrials_resource:4aaeb1ce2dea250ee19040786353f6a7]
Safety of cell injections was assessed by reviewing adverse events at 3 time points: (1) up to 2 weeks post-procedure), (2) 3 months post-procedure, and (3) at 6 months post-procedure. Major adverse events were adjudicated (hospitalization, arrhythmia, exacerbation of congestive HF [CHF], acute coronary syndrome, myocardial infarction, stroke, or death).
Bio2RDF identifier
4aaeb1ce2dea250ee19040786353f6a7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4aaeb1ce2dea250ee19040786353f6a7
measure [clinicaltrials_vocabulary:measure]
Safety of Autologous-bone-marrow Injections
time frame [clinicaltrials_vocabulary:time-frame]
up to 2 weeks post-procedure, 3 months and 6 months
description
Safety of cell injections was ...... infarction, stroke, or death).
identifier
clinicaltrials_resource:4aaeb1ce2dea250ee19040786353f6a7
title
Safety of Autologous-bone-marr ...... ocedure, 3 months and 6 months
@en
type
label
Safety of Autologous-bone-marr ...... eb1ce2dea250ee19040786353f6a7]
@en